Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mBoost
NCT05057182Phase 4Completed
- Sponsor
- The University of Hong Kong
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by The University of Hong Kong. Started Oct 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05057182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057182.